Sobi starts rolling application for refractory gout drug SEL-212 in the US, hoping to take on Amgen’s Krystexxa in the market.

Episode 8: Frequently asked questions about gout and uncontrolled gout Brian LaMoreaux, MD, MS, answers frequently asked questions, with topics including: how to define uncontrolled gout, how to ...

For patients with gout who cannot get relief using standard therapies, daily life can be a painful, debilitating experience. Now, phase 3 results with a new drug from Sobi and Selecta suggests ...